当前位置: 首页 >> 检索结果
1. Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.
作者: Thierry Passeron.;Vimal H Prajapati.;Raja K Sivamani.;Khaled Ezzedine.;Nanja van Geel.;Iltefat Hamzavi.;Amit G Pandya.;David Rosmarin.;Leihong Xiang.;Tamio Suzuki.;Seemal Desai.;Mehdi Rashighi.;Smitha Suravaram.;Irina Fish.;Xiaofei Hu.;Xiaoqiang Wu.;Minglu Wang.;Yao Yu.;Ahmed M Soliman.;Heidi S Camp.;Henrique D Teixeira.;Stavonnie Patterson.;Bethanee J Schlosser.;Julien Seneschal.
来源: Lancet. 2026年408卷10555期636-648页
Non-segmental vitiligo is an autoimmune inflammatory disease characterised by loss of melanocytes leading to skin depigmentation. No systemic therapies have been approved, and additional therapeutic options are needed. Here, we report the efficacy and safety of upadacitinib, a selective once-daily Janus kinase inhibitor, in adults and adolescents with non-segmental vitiligo.
2. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
作者: Pablo Mora.;Vanita R Aroda.;Marisse Asong.;Matthias Blüher.;Line Dam Heftdal.;Amanda-Louise Fenger Carlander.;Louise Nygaard Vilsen.;Julio Rosenstock.
来源: Lancet. 2026年408卷10555期621-635页
Zenagamtide (formerly amycretin) is a unimolecular agonist of GLP-1, amylin, and calcitonin receptors. We aimed to investigate the dose-response relationship with respect to the efficacy and safety of once-weekly subcutaneous zenagamtide compared with placebo in adults with type 2 diabetes.
3. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
作者: Pablo Mora.;Vanita R Aroda.;Marisse Asong.;Matthias Blüher.;Amanda-Louise Fenger Carlander.;Morten Kaltoft.;Louise Nygaard Vilsen.;Julio Rosenstock.
来源: Lancet. 2026年408卷10555期607-620页
Zenagamtide (formerly amycretin) is a unimolecular peptide agonist of GLP-1, amylin, and calcitonin receptors. We aimed to investigate the dose-response relationship with respect to the efficacy and safety of once-daily oral zenagamtide compared with placebo in adults with type 2 diabetes.
4. Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study.
作者: Vallerie V McLaughlin.;Derek Solum.;Daniel Lachant.;Ali Ataya.;Joan A Barberà.;Gisela Bohns Meyer.;Sung-A Chang.;Richard Channick.;Colin Church.;John Feenstra.;Sean Gaine.;George Giannakoulas.;Carlos Jerjes-Sanchez.;Dinesh Khanna.;Nick H Kim.;Ronald Oudiz.;Ioana R Preston.;Namita Sood.;Fernando Torres.;Jean-Luc Vachiery.;Tomás Pulido.;Dana Cella.;Chunqin Deng.;Miluska Escudero.;Victoria Lacasse.;Leigh Peterson.;Raymond Benza.;Marc Humbert.; .
来源: Lancet. 2026年408卷10554期521-531页
Pulmonary arterial hypertension (PAH) is a rare, progressive disease characterised by elevated pulmonary vascular resistance that can lead to right ventricular failure and premature death. Ralinepag is an oral, once-daily, selective prostacyclin IP receptor agonist developed to treat PAH. We aimed to evaluate the efficacy and safety of ralinepag in patients with PAH.
5. Oral step-down, optimal drug, and total duration of antibiotic treatment in African children hospitalised with severe community-acquired pneumonia (PediCAP): a factorial randomised controlled trial.
作者: Julia A Bielicki.;Michelle Clements.;Victor Musiime.;David P Moore.;Muhammad Sidat.;Veronica Mulenga.;Constantine Mutata.;Damalie Nalwanga.;Zainab Waggie.;Josina Chilundo.;Chishala Chabala.;Mutsawashe Bwakura-Dangarembizi.;Moherndran Archary.;Andrew Kiggwe.;Ziyaad Dangor.;Ben Spittle.;Monica Kapasa.;Abner Tagoola.;Charity Jeki.;Jahit Sacarlal.;W Chris Buck.;Shula Chanda.;Hilda A Mujuru.;Carlo Giaquinto.;Shabir A Madhi.;A Sarah Walker.;Mike Sharland.; .
来源: Lancet. 2026年408卷10554期545-557页
WHO recommends 5 days of intravenous antibiotics for children hospitalised with severe community-acquired pneumonia (CAP). We aimed to investigate the safety of a step-down to different oral antibiotics and the shortest effective duration.
6. High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.
作者: Gerald Illerhaus.;Andrés J M Ferreri.;Julia Wendler.;Mascha Binder.;Peter Borchmann.;Justin Hasenkamp.;Stephan Stilgenbauer.;Alexander Röth.;Gerlinde Egerer.;Thomas Ernst.;Thomas Weber.;Bernd Hertenstein.;Georg Lenz.;Martin Dreyling.;Robert Möhle.;Guido Kobbe.;Christian A Schmidt.;Uta Brunnberg.;Jens Panse.;Michael Kneba.;Thomas Heinicke.;Sebastian Schroll.;Thomas S Larsen.;Lorenz Thurner.;Tobias Pukrop.;Hans Salwender.;Ralph Naumann.;Georg Hess.;Frank P Kroschinsky.;Anne K Blystad.;Ulrich Keller.;Elisa J Pulczynski.;Martin Bjerregård Pedersen.;Francesca Re.;Lorella Orsucci.;Lisa Pospiech.;Paul La Rosée.;Martina Deckert.;Maurilio Ponzoni.;Dennis Gmehlin.;Matthias Backenstrass.;Antje Jensch.;Elke Valk.;Teresa Calimeri.;Benjamin Kasenda.;Martin Trepel.;Heidi Fricker.;Inna Semenova.;Florian Scherer.;Philipp von Gottberg.;Elvira Burger.;Olga Grishina.;Claudia Hader.;Gabriele Ihorst.;Jürgen Finke.;Emanuele Zucca.;Elisabeth Schorb.
来源: Lancet. 2026年408卷10554期532-544页
Consolidation therapy for primary CNS lymphoma (PCNSL) includes high-dose chemotherapy with autologous stem-cell transplantation (HCT-ASCT), yet its efficacy compared with non-myeloablative chemoimmunotherapy remains uncertain. This study aimed to provide randomised comparative evidence on the efficacy and safety of thiotepa-based HCT-ASCT versus non-myeloablative R-DeVIC consolidation after uniform MATRix induction in newly diagnosed PCNSL.
7. 1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.
作者: Yohei Sotomi.;Ken Kozuma.;Yoshiharu Higuchi.;Gaku Nakazawa.;Yoshihiro Morino.;Kenji Ando.;Junya Ako.;Kengo Tanabe.;Takashi Muramatsu.;Ken Kobayashi.;Yasuhiro Ichibori.;Takayuki Ishihara.;Keiji Hirooka.;Satoru Suwa.;Takayuki Warisawa.;Toru Naganuma.;Atsushi Kikuchi.;Ryu Shutta.;Naotaka Okamoto.;Yasuhiro Tanabe.;Atsunori Okamura.;Kosuke Kashiwabara.;Shungo Hikoso.;Yasushi Sakata.; .
来源: Lancet. 2026年408卷10553期440-452页
The optimal duration of dual antithrombotic therapy after percutaneous coronary intervention (PCI) in patients with atrial fibrillation remains uncertain. We aimed to compare the efficacy and safety of 1-month versus 12-month dual antithrombotic therapy in this population.
8. Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.
作者: Lucia Crivelli.;Claudia Kimie Suemoto.;Ana Luisa Sosa.;Francisco Lopera.;David Aguillón.;Ricardo Francisco Allegri.;Ricardo Nitrini.;Ismael Luis Calandri.;Lina Velilla-Jiménez.;Mônica Sanches Yassuda.;Natalia Acosta-Baena.;Rosa María Salinas.;Ana Charamelo.;Carolina Delgado Derio.;Daisy Miguelina Acosta.;Jorge Mario León-Salas.;Lissette Duque-Peñailillo.;María Isabel Cusicanqui.;Nilton Custodio.;Adriana Anchia-Alfaro.;Alberto Núñez-Herrera.;Alejandra De Rubens.;Alice Leites.;Ana Vigil-Martínez.;Andrés Damian.;Beatriz María Flores-Blanco.;Belén Custodio.;Carlos Laforcada.;Carlos Márquez.;Clarisse Vasconcelos Friedlaender.;Clara Gabriela Espinoza-Cruz.;Cristina Cañadas.;Cristiane Peixoto.;Darina Helen Muñoz.;Diego Fernández Slezak.;Elainy Felix.;Esteban Aguirre-Salvador.;Ezequiel Ignacio Surace.;Francesca Mariani.;Gabriela Rojas De La Torre.;Graciet Verástegui.;Greta Keller.;Gustavo Henrique Peixoto.;Handel Arturo Morilla.;Ivonne Z Jiménez-Velázquez.;Jamileth Yasmín More.;Javiera Francisca Rodríguez.;Jéssica Abdo Gonçalves Tosatti.;João Victor de Faria Rocha.;Jonathan Saldarriaga-Hernández.;José Carlos Huilca.;José Tomás García-Molina.;Joyce Graciela Martínez-Galindo.;Juan Carlos Duran.;Juana Guillermina Rodriguez.;Karina Braga Gomes.;Karolina Gouveia César-Freitas.;Katherine Agüero.;Lara Mora-Villalobos.;Laura Osorio Asprilla.;Leonardo Cruz de Souza.;Ligia Soto.;Lucia Cortabarría.;Lucy Baldeón.;Luzia Lima Carreira.;Lizeth Marin-Buitrago.;Maira Camila Moreno.;Maira Tonidandel Barbosa.;Maren Torheim.;Maria Aquimara Zambone Magalhães.;Maria da Graça Morais Martin.;Maria Eugenia Martin.;Melissa Francisca Torres.;Mercedes Menéndez.;Micaela Anahi Hernandez.;Mónica Sánchez Granizo.;Myriam Gutiérrez.;Nicolás Corvalán.;Paula Jimena Mora.;Pedro Peguero.;Rocío Ramírez-Santos.;Rodrigo Sebastian Fernández.;Rosa Montesinos.;Sebastian Ospina-Henao.;Silvia Ysabel Montes.;Sofía Santero.;Sonia Maria Dozzi Brucki.;Sylvia Josephy-Hernandez.;Tomas Casildo Vazquez.;Yanina Bérgamo.;Yamile Bocanegra.;Yleana Altagracia Muñoz.;Yosselin Vicuña.;Zoraida Del Carmen Lora.;Miia Kivipelto.;Rema Raman.;Mark A Espeland.;Laura D Baker.;Heather M Snyder.;Gustavo Emilio Sevlever.;María C Carrillo.;Paulo Caramelli.; .
来源: Lancet. 2026年408卷10553期417-429页
Latin America faces a high dementia burden, with increased prevalence of factors associated with cognitive decline. Multidomain lifestyle interventions might delay cognitive decline, but populations from Latin America remain under-represented in dementia prevention trials. We aimed to investigate the feasibility of a culturally adapted, multidomain, systematic lifestyle intervention and investigate its effects on global cognitive function in at-risk older adults (aged 60-77 years).
9. Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.
作者: Francesco Cogliati Dezza.;Lydia Barrera Pulido.;Irene Borreguero Borreguero.;Fernando Docobo Pérez.;Virginia Palomo Jiménez.;Sandra de la Rosa Riestra.;José María Bravo-Ferrer.;Zaira Raquel Palacios-Baena.;Miguel Ángel López Zuñiga.;Fernando Cobo.;Joan Gómez-Junyent.;Juan P Horcajada.;Esperanza Merino.;Mónica Parra.;Joaquín López-Contreras.;Alba Rivera.;Dolores Sousa Regueiro.;Martín Pampín Garcia.;Salvador López Cardenas.;María Carmen Gómez Sánchez.;Inés Pérez Camacho.;Sergio Manuel Martín Ramos.;Eva León Jiménez.;Ana Isabel Aller García.;M Teresa Pérez-Rodríguez.;Adrián Sousa.;Maria Siller Ruiz.;Francisco Arnaiz de Las Revillas Almajano.;Laura Gisbert Pérez.;Josune Goikoetxea Agirre.;Ángela Cano.;Francisco Javier Martínez-Marcos.;María José García País.;Rosa Escudero Sánchez.;Sofía de la Villa.;José Ramón Yuste Ara.;María Ángeles Esteban-Moreno.;Andrés Ruiz-Sancho.;Marc Pedrosa Aragón.;Jorge Alba Fernández.;Ana María Barrios Blandino.;Helem Haydeé Vilchez-Rueda.;Rocío Álvarez-Marín.;Alberto Romero Palacios.;Elisa García Vázquez.;Enrique Nuño Álvarez.;Clara Rosso-Fernández.;Belén Gutiérrez-Gutiérrez.;Álvaro Pascual.;Lorena López-Cerero.;Jesús Rodríguez-Baño.; .
来源: Lancet. 2026年408卷10553期430-439页
Alternatives to carbapenems for the treatment of third-generation cephalosporin-resistant Enterobacterales (3GCR-E) are urgently needed to reduce the selection pressure posed by these drugs. Temocillin is a neglected narrow-spectrum β-lactam. The aim of the trial was to investigate if temocillin is non-inferior to carbapenems for the targeted treatment of bacteraemia due to 3GCR-E.
10. Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.
作者: Matthew S Davids.;Toby A Eyre.;Jennifer A Woyach.;Lindsey E Roeker.;Alessandra Ferrajoli.;Yucai Wang.;Constantine S Tam.;Wojciech Jurczak.;Pier Luigi Zinzani.;Martin Šimkovič.;Jian-Yong Li.;Francesc Bosch.;Damien Roos-Weil.;Paula Cramer.;Anders Osterborg.;Prioty Islam.;Ryan Jacobs.;Alan Skarbnik.;Seema A Bhat.;Suhyun Kang.;Min Chen.;Bastien Nguyen.;Samuel C McNeely.;Karen Lee Chung.;Joana M Oliveira.;Rodrigo Ito.;Paolo Ghia.;William G Wierda.
来源: Lancet. 2026年408卷10553期453-470页
Venetoclax-rituximab (VR) following covalent Bruton tyrosine kinase (BTK) inhibitor therapy is the fixed-duration standard of care for patients with chronic lymphocytic leukaemia (including small lymphocytic lymphoma). Pirtobrutinib, a non-covalent BTK inhibitor, is approved for use after treatment with a covalent BTK inhibitor as a continuous therapy option. We aimed to evaluate the addition of pirtobrutinib to VR as a fixed-duration regimen in patients with relapsed or refractory chronic lymphocytic leukaemia.
11. Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.
作者: Olivier van Minnen.;Annemieke Oude Lansink-Hartgring.;Rombout B E van Amstel.;Bas van den Bogaard.;Jeroen J H Bunge.;Thijs S R Delnoij.;Joep M Droogh.;Laurien van Koppenhagen.;Carlos V Elzo Kraemer.;Marijn Kuijpers.;Jacinta J Maas.;Jesse de Metz.;Marcel C G van de Poll.;S Jorinde Raasveld.;Dinis Dos Reis Miranda.;Priya Vart.;Karin M Vermeulen.;Alexander P J Vlaar.;Walter M van den Bergh.; .
来源: Lancet. 2026年408卷10552期357-366页
In patients receiving extracorporeal membrane oxygenation (ECMO), standard practice is full-dose intravenous unfractionated heparin (UFH) targeting an activated partial thromboplastin time of 2·0-2·5 times baseline to reduce thrombotic risk. This approach can increase bleeding without further reducing thrombosis compared with low-dose UFH. Robust evidence to guide anticoagulation targets is absent because anticoagulation targets in ECMO have never been assessed in a sufficiently powered randomised trial. We aimed to determine whether low-dose UFH or therapeutic low-molecular-weight heparin (LMWH) is non-inferior to standard-dose UFH in patients receiving ECMO.
12. [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.
作者: Thomas Walter.;Henning Jann.;Catherine Ansquer.;Emmanuel Deshayes.;Rocio Garcia-Carbonero.;Alexandre Teulé.;Richard P Baum.;Hein J Verberne.;Jarosław B Ćwikła.;Rajaventhan Srirajaskanthan.;Louis de Mestier.;Chiara M Grana.;Andreas Buck.;Dieter Hörsch.;Marianne Pavel.;Lawrence O Dierickx.;Michael Michael.;Jonathan Strosberg.;Attila Kollár.;Paula Jimenez-Fonseca.;Anja Rinke.;Maribel Del Olmo-García.;Anthime Flaus.;Jorge Hernando.;Andreas Kluge.;Monika Breuninger.;Serhii Melnyk.;Konstantin Zhernosekov.;Jaume Capdevila.; .
来源: Lancet. 2026年408卷10551期234-247页
Peptide receptor radionuclide and targeted therapy are both approved treatment options for patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP NETs), but clinical evidence for preferred sequencing is scarce. The COMPETE trial evaluated the efficacy and harms of peptide receptor radionuclide therapy ([177Lu]Lu-edotreotide) versus targeted molecular therapy (everolimus) in patients with advanced, progressive, somatostatin receptor-positive GEP NETs.
13. Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.
作者: Nils P Hailer.;Xavier L Griffin.;Sebastian Mukka.;Tatevik Ghukasyan Lakic.;Duncan Appelbe.;Olof Sköldenberg.;Sarah E Lamb.;Ollie Östlund.;Olof Wolf.; .
来源: Lancet. 2026年408卷10552期348-356页
Dislocation is the most common early surgical complication in patients with hip fractures treated with total hip replacement (THR). Dual mobility total hip replacement (DM-THR) was developed to increase joint stability, but no randomised trial has investigated its efficacy and safety. We aimed to compare the risk of dislocation in patients receiving DM-THR versus conventional THR.
14. Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial.
作者: Hao Huang.;Shabei Xu.;Tingting Qin.;Minghuan Wang.;Guo Li.;Chenchen Liu.;Gang Deng.;Yihui Wang.;Donghui Ao.;Yi Xie.;Yi Zhang.;Qianqian Kong.;Lingning Lan.;Ying Yu.;Shanshan Huang.;Zhiyuan Yu.;Tingyu Yi.;Wenhuo Chen.;Wenlong Zhao.;Junfeng Su.;Peiyang Zhou.;Fengguang Li.;Bin Mei.;Ping Jing.;Jinwu Zhang.;Jie Du.;Mayank Goyal.;Thanh N Nguyen.;Duolao Wang.;Jeffrey L Saver.;Zhouping Tang.;Wei Wang.;Xiang Luo.; .
来源: Lancet. 2026年408卷10551期263-274页
Successful reperfusion after endovascular thrombectomy does not consistently result in functional independence in acute ischaemic stroke. We aimed to assess the efficacy and safety of tirofiban, a glycoprotein IIb/IIIa receptor antagonist, given to patients with acute ischaemic stroke who had had a successful endovascular reperfusion.
15. Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study.
作者: Lars H Lund.;Arantxa Barandiarán Aizpurua.;Entela Bollano.;Oscar Braun.;Jan Leendert P Brouwer.;Jan W Buikema.;Antonio Cannata.;Roy S Gardner.;M Louis Handoko.;Chim C Lang.;Marco Metra.;Gianfranco Sinagra.;Tonje Thorvaldsen.;Robert M A van der Boon.;Bart J van Essen.;Sanjiv J Shah.;Adriaan A Voors.;Carolyn S P Lam.;Bertram Pitt.;Scott D Solomon.;Camilla Hage.;Marcus Stahlberg.;Alberto Bernareggi.;Allan Gordon.;Marianna Del Sole.;Elin Rosendahl.;Patrik Stromberg.;Goran Westerberg.;Robert Edfors.;Mark C Petrie.
来源: Lancet. 2026年408卷10551期248-262页
The central problem in heart failure with reduced ejection fraction (HFrEF) is reduced contractility. Existing inotropes are associated with adverse effects. In this exploratory study, we aimed to assess the safety and tolerability of AC01, a novel oral calcium-sensitising inotrope and ghrelin receptor agonist, in patients with HFrEF.
16. Patellar resurfacing in total knee replacement: 20-year clinical and economic results of a large multicentre, randomised controlled trial in the UK.
作者: David W Murray.;Jemma Hudson.;Helen Dakin.;Graeme MacLennan.;Matthew Little.;Alastair Gray.;Suzanne Breeman.;Marion K Campbell.
来源: Lancet. 2026年408卷10549期52-61页
There is conflicting evidence regarding the merits of patellar resurfacing during total knee replacement (TKR), as previous randomised controlled trials (RCTs) have been under-powered and with follow-up of ten years or less.
17. Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial.
Previously considered rare, penicillin-susceptible Staphylococcus aureus (PSSA) bacteraemia has re-emerged worldwide. Although benzylpenicillin might offer advantages in terms of pharmacokinetic and adverse effect profiles, anti-staphylococcal penicillins are recommended for serious infections because of concern over undetected penicillin resistance. We aimed to compare benzylpenicillin with anti-staphylococcal penicillins (cloxacillin or flucloxacillin) for the treatment of PSSA bacteraemia in adults.
18. Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.
作者: Meletios A Dimopoulos.;Fredrik Schjesvold.;Chengcheng Fu.;Monique A Hartley-Brown.;Cesar Gomez.;Donna Reece.;Gabor Mikala.;Omar Alkharabsheh.;Christopher Parrish.;Edvan de Queiroz Crusoé.;Kenny Gálvez.;Henry Idrobo.;Darrell White.;Ridhi Gupta.;Cindy Lee.;Chia-Jen Liu.;Hang Quach.;Yafei Wang.;Claudio Cerchione.;Cecily Forsyth.;Vania Hungria.;Pritam Kalaskar.;Vasko Graklanov.;Phoebe Joy Ho.;Maika Klaiber-Hakimi.;Yok Lam Kwong.;Martha Louzada.;Amitabha Mazumder.;Oliver Miles.;Chandramouli Nagarajan.;Sripada V S S Prasad.;Marc S Raab.;Gergely Varga.;Eyck von der Heyde.;Zhongjun Xia.;Paola Andrea Ochoa.;Albert Oriol.;Junichiro Yuda.;Junya Kuroda.;Jing Gong.;Zehua Zhou.;Paulo Maciag.;Brian Yu.;Alberto Rocci.;Phillip Koo.;Jessica Katz.;Paul G Richardson.; .
来源: Lancet. 2026年408卷10551期219-233页
A growing number of patients with multiple myeloma are anti-CD38 antibody-exposed and lenalidomide-exposed at first relapse, subsequently limiting their treatment options. Mezigdomide, a potent cereblon E3 ligase modulator, induces maximal, rapid Ikaros and Aiolos degradation, resulting in enhanced myeloma cell cytotoxicity and immune stimulation versus immunomodulatory drugs. The SUCCESSOR-2 trial evaluates the efficacy and safety of mezigdomide in combination with carfilzomib and dexamethasone versus carfilzomib plus dexamethasone.
19. Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.
作者: Vanita R Aroda.;Melanie J Davies.;Jill Maaske.;Marcus Millegård.;Víctor López Juan.;Jens Aberle.;Andreea Ciudin.;Rory J McCrimmon.;Olof Eklund.;Judy L Shih.;Mikaela Sjostrand.;Donna Zarzuela.;Julio Rosenstock.
来源: Lancet. 2026年407卷10547期2515-2527页
Elecoglipron is an oral, small molecule glucagon-like peptide (GLP)-1 receptor agonist currently in development for the management of type 2 diabetes. Elecoglipron is orally administered once daily with no food or fluid restrictions. SOLSTICE, a phase 2b study, evaluated the efficacy, safety, and tolerability of elecoglipron versus placebo in participants with type 2 diabetes.
20. Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
作者: Michelle Welch.;Thomas Forst.;Weiping Jia.;Pedro Orozco Del Pino.;Max Denning.;Wen-Shuo Wu.;Jianghao Li.;Rong Liu.;Michele Eifu.;Yanyun Chen.; .
来源: Lancet. 2026年408卷10550期125-140页
Type 2 diabetes is a complex metabolic disorder often requiring combination therapy for optimal glycaemic control. This study assessed the efficacy and safety of orforglipron, an oral, non-peptide GLP-1 receptor agonist, versus dapagliflozin, an oral SGLT2 inhibitor, in participants with type 2 diabetes and inadequate glycaemic control with metformin.
|